miRNAs对心肌重塑和心力衰竭调控作用的研究进展  

Advances in the regulation of miRNAs on myocardial remodeling and heart failure

作　　者：昌薇[1,2] 吴青青[1] 肖杨[1] 唐其柱[1] CHANG Wei1,2, WU Qingqing1, XIAO Yang1, TANG Qizhu1(1Department of Cardiology, Renmin Hospital of Wuhan University, Cardiovascular Research Institute of Wuhan University, Hubei Key Laboratory of Cardiology, Wuhan, 430060, China;2Department of Cardiology, the First Hospital of Wuha)

机构地区：[1]武汉大学人民医院心内科武汉大学心血管病研究所心血管病湖北省重点实验室,武汉430060 [2]武汉市第一医院心内科

出　　处：《临床心血管病杂志》2018年第3期218-221,共4页Journal of Clinical Cardiology

基　　金：国家自然科学基金(No:81470516);中国博士后科学基金(No:2016M592392);国家科技支撑计划项目(No:2015BAI09B06)

摘　　要：心力衰竭是绝大多数心血管疾病的共同终末阶段,而心肌重塑是心力衰竭发生及发展的重要过程。引发心肌重塑与心力衰竭的调控机制极其复杂,目前尚不十分清楚。近年来,越来越多的研究表明,miRNAs通过调控相关靶基因的表达参与了心肌重塑和心力衰竭的发生发展。本文重点阐述miRNAs在心肌重塑及心力衰竭发生发展过程中的调控作用的新研究进展,并对其临床应用的前景予以展望。Heart failure is the common terminal stage of various cardiovascular diseases, and myocardial remodeling is the decisive process of the development of heart failure. Myocardial remodeling and heart failure regulation mechanism is extremely complex and unclear. In recent years, more and more studies have shown that miRNAs are involved in the development of cardiac hypertrophy, myocardial fibrosis and heart failure by regulating the expression of related target genes. This paper focuses on the regulation of miRNAs in myocardial remodeling and heart failure, and provides a prospect for miRNAs in the clinical application of cardiovascular disease.

关 键 词：MIRNAS 心肌重塑 心肌肥厚 心肌纤维化 心力衰竭 

分 类 号：R541.6[医药卫生—心血管疾病]